ROCKVILLE, Md., April 27, 2021 /PRNewswire/ -- REGENXBIO
Inc. (Nasdaq: RGNX) today announced that four oral and nine
poster presentations will be presented at the American Society of
Gene and Cell Therapy's 24th Annual Meeting taking place
from May 11 to 14, 2021, in virtual
format. Presentations and posters will be available at
https://www.asgct.org/.
Oral presentations include:
Abstract Title: Effects of Sexual Dimorphism and
Genetic Background on AAV Tissue Transduction in Mice Following
Intravenous Administration of a Diverse Capsid Pool (abstract
#94)
Presenter: Elad Firnberg,
Ph.D., Scientist II, Gene Transfer Technologies, REGENXBIO
Session Title: Novel Factors in AAV Transduction and
AAV Genomes
Date/Time: Wednesday, May 12, 2021 from 6:00 to 6:15 p.m. ET
Abstract Title: Intravenous Administration of a
Barcoded and Pooled AAV Library for the Comprehensive
Characterization and Comparison of Capsid Tropisms (abstract
#189)
Presenter: April Giles,
Ph.D., Scientist II, Gene Transfer Technologies, REGENXBIO
Session Title: Novel AAV Biology and Platform
Technologies
Date/Time: Thursday, May 13,
2021 from 6:00 to 6:15 p.m.
ET
Abstract Title: High-Throughput Screening of AAV
Productivity to Enable Rapid Capsid Characterization (abstract
#192)
Presenter: Jenny Egley,
Scientist, Gene Transfer Technologies, REGENXBIO
Session Title: Novel AAV Biology and Platform
Technologies
Date/Time: Thursday, May 13, 2021 from 6:45 to 7:00 p.m. ET
Abstract Title: RGX-121 Gene Therapy for the
Treatment of Severe Mucopolysaccharidosis Type II: Interim Analysis
of the First in Human Study (abstract #215)
Presenter: Roberto Giugliani, M.D., Ph.D.,
Professor, Department of Genetics, UFRGS, Medical Genetics
Service, HCPA, Porto Alegre,
Brazil
Session Title: Gene Therapy for Lysosomal Storage
Disorders
Date/Time: Friday, May 14, 2021 from 12:15 to 12:30 p.m. ET
Poster presentations include:
Abstract Title: Identification of Transcriptional
Start Sites in a Tandem Promoter by 5'-RACE and NGS (abstract
#317)
Presenter: Kirk Elliot,
Senior Associate Scientist, REGENXBIO
Session Title: AAV Vectors - Virology and
Vectorology
Date/Time: Tuesday, May 11, 2021 from 8:00 to 10:00 a.m. ET
Abstract Title: Comparative Cardiac, Neurologic, and
Skeletal Effectiveness of Intravenous and Intrathecal AAV9-IDUA
Delivered Individually or Combined in a Murine Model of
Mucopolysaccharidosis Type I (abstract #490)
Presenter: Lalitha Belur,
Ph.D., Assistant Professor Genetics, Cell
Bio at University of Minnesota
Session Title: Metabolic, Storage, Endocrine, Liver and
Gastrointestinal Diseases
Date/Time: Tuesday, May 11, 2021 from 8:00 to 10:00 a.m. ET
Abstract Title: Comprehensive Evaluation of an AAV
Library in the Mice and Nonhuman Primate Ocular Tissues Following
Intravitreal Delivery (abstract #568)
Presenter: Wei-Hua Lee,
Ph.D., Scientist II, Research and Early Development, Target
Discovery, REGENXBIO
Session Title: Neurologic Diseases
Date/Time: Tuesday, May 11, 2021 from 8:00 to 10:00 a.m. ET
Abstract Title: RGX-202, an AAV8 Vector Encoding an
Extended Microdystrophin Efficiently Restores Dystrophin Associated
Protein Complex and Corrects Satellite Cells in a Dystrophic Mouse
Model (abstract #597)
Presenter: Chunping Qiao,
Ph.D., Principal Scientist, REGENXBIO
Session Title: Musculo-Skeletal Diseases
Date/Time: Tuesday, May 11, 2021 from 8:00 to 10:00 a.m. ET
Abstract Title: A Novel AAV8 Vector for
Microdystrophin Gene Therapy of Duchenne Muscular Dystrophy:
Preclinical Studies in the MDX Mouse (abstract #614)
Presenter: SunJung Kim,
Ph.D., Senior Scientist, Pharmacology and Toxicology, Preclinical
Development, REGENXBIO
Session Title: Musculo-Skeletal Diseases
Date/Time: Tuesday, May 11, 2021 from 8:00 to 10:00 a.m. ET
Abstract Title: A Case Study on Viral Clearance for
a Downstream AAV Process using a Model Virus Panel and
Non-Infectious MVM Surrogate (abstract #877)
Presenter: Shaojie Weng,
Scientist II
Session Title: Pharmacology/Toxicology Studies or Assay
Development
Date/Time: Tuesday, May 11, 2021 from 8:00 to 10:00 a.m. ET
Abstract Title: Assessment of Inflammatory and
Neurodegenerative Biomarkers in NHPs with DRG Toxicity (abstract
#889)
Presenter: Ryan Reddinger,
Ph.D., Scientist I, Preclinical Development, REGENXBIO
Session Title: Pharmacology/Toxicology Studies or Assay
Development
Date/Time: Tuesday, May 11, 2021 from 8:00 to 10:00 a.m. ET
Abstract Title: Quantification of Double-Stranded
RNAs Produced by AAV Vectors: A Methodological Reassessment
(abstract #891)
Presenter: Chunping Qiao,
Ph.D., Principal Scientist, REGENXBIO
Session Title: Pharmacology/Toxicology Studies or Assay
Development
Date/Time: Tuesday, May 11, 2021 from 8:00 to 10:00 a.m. ET
Abstract Title: Identification of a Kidney Specific
AAV Following Insertion of Tissue Homing Peptides in Variable
Region IV (abstract #292)
Presenter: Samantha A. Yost,
Ph.D., Scientist II, Gene Transfer Technologies, REGENXBIO
Session Title: AAV Vectors - Virology and Vectorology
Date/Time: Tuesday, May 11, 2021 from 8:00 to 10:00 a.m. ET
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking
to improve lives through the curative potential of gene therapy.
REGENXBIO's NAV Technology Platform, a proprietary adeno-associated
virus (AAV) gene delivery platform, consists of exclusive rights to
more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and
AAVrh10. REGENXBIO and its third-party NAV Technology Platform
Licensees are applying the NAV Technology Platform in the
development of a broad pipeline of candidates in multiple
therapeutic areas.
Contacts:
Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
Brendan Burns, 212-600-1902
brendan@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-american-society-of-gene-and-cell-therapys-24th-annual-meeting-301278430.html
SOURCE REGENXBIO Inc.